CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.
Home/Biomarker

RET mutation (medullary thyroid cancer)

Gene: RET · Type: mutation

Indications: Thyroid cancer

SensitivityResistanceCIViC Context

FDA Sensitivity Assertions

DrugIndicationRecommendationFDA SourceLink
SelpercatinibThyroid cancerINDICATED
FDA Label
Label
PralsetinibThyroid cancerINDICATED
FDA Label
Label
CabozantinibThyroid cancerINDICATED
FDA Label
Label
VandetanibThyroid cancerINDICATED
FDA Label
Label